{"id":"bcg-sii","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (erythema, induration)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2108905","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BCG (Bacillus Calmette-Guérin) is a live attenuated mycobacterial vaccine that activates both innate immunity through pattern recognition receptors and adaptive immunity through T-cell and B-cell responses. The Sii strain variant from the Serum Institute of India is being investigated for enhanced immunogenicity. In phase 3 development, it is being studied for potential therapeutic applications beyond traditional tuberculosis prevention.","oneSentence":"BCG Sii is a live attenuated Mycobacterium bovis BCG vaccine strain designed to stimulate innate and adaptive immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:44.184Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention or therapeutic immunization (investigational)"}]},"trialDetails":[{"nctId":"NCT06997367","phase":"PHASE2","title":"Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)","status":"RECRUITING","sponsor":"Bharat Biotech International Limited","startDate":"2025-03-01","conditions":"Tuberculosis (TB)","enrollment":164},{"nctId":"NCT04351685","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2020-11-09","conditions":"Mycobacterium Tuberculosis Infection","enrollment":6940},{"nctId":"NCT02380508","phase":"NA","title":"Heterologous Effects of BCG in Healthy UK Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-02","conditions":"Tuberculosis","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bacille Calmette-Guérin Serum Institute of India"],"phase":"phase_3","status":"active","brandName":"BCG Sii","genericName":"BCG Sii","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BCG Sii is a live attenuated Mycobacterium bovis BCG vaccine strain designed to stimulate innate and adaptive immune responses. Used for COVID-19 prevention or therapeutic immunization (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}